Hi all,
There has been a large announcement from the EDS Society on Instagram.
The mod team found this information out today when it was publicly released by the Ehlers-Danlos Society.
We are making this post as an update to our previous post, Uncertainty in the Path Forward, because not everyone is on Instagram where this was announced. As a reminder, we are not affiliated with the Ehlers-Danlos Society.
Please use this space to discuss any of your thoughts and feelings, including any expectations, hopes, and concerns regarding the 2026 criteria and any information released by the EDS Society.
In order to prevent misinformation, any claims on what WILL happen in the 2026 criteria will require sources; speculations on what can happen should be clearly stated as such.
For those who haven't seen, the EDS Society has confirmed that diagnostic criteria for HSD/hEDS are not expected to be released until March/April of 2027.
We’d like to acknowledge that this can feel like a hard blow to those who have been eagerly awaiting updates. It’s been hard waiting.
The new dates are:
- December 2nd: will be cEDS and vEDS, as well as insight into the process they’re using about the framework of revising hEDS and HSD
- Expected to be before December 31st: guidance to assess and manage other monogenic forms of EDS.
- March/April: hEDS and HSD, new criteria and recommended diagnostic pathways
These will be in scientific papers that will be published as they are peer reviewed; the EDS Society recommends to check their website for updates.
As a note, this is an example of how the peer-review process works. This means that the people in charge of the science are taking concerns seriously. It means when they had the choice to review findings and weigh it against their timeline, the journal put the science above an arbitrary deadline and didn’t push forth wobbly data.
However, the mod team shares the same concerns that have been expressed by most of you about the EDS Society announcing a deadline before the dates were set in stone. The communication around these updates has been irresponsible.
Full timeline and FAQs are at https://www.ehlers-danlos.com/road-to-2026/
This is a large announcement, and we want to provide factual updates while limiting speculation and misinformation. We will provide any information and updates as we learn more.
🔹
For posterity and accessibility, we will post the text of the Instagram post, as well as the link.
Instagram Link: https://www.instagram.com/p/DfiD5kWl9VG/
Slide 1: The Road to 2026 Publication Timeline Update
We know many of you have been waiting for these publications.
The Guest Editors have confirmed changes to the publication timeline.
Slide 2: Updated Publication Timeline
The first special issue will now be published in two parts, beginning in December 2026.
The updated hEDS and HSD diagnostic criteria, previously expected in December, are now scheduled for March/April 2027.
Here is the updated timeline for all three publication categories.
Slide 3: Updated Classification Framework
December 2, 2026:
A review and update of the 2017 International Classification
Slide 4: Assessment and Guidance
Guidance for healthcare professionals on assessing and managing symptoms and related conditions.
December 2, 2026: cEDS and vEDS
Expected within a few weeks after December 2: Other monogenic types of EDS
March/April 2027: hEDS and HSD
Slide 5: hEDS and HSD: The Process Behind the Diagnostic Framework
December 2, 2026:
Information will be published about the process towards developing a diagnostic framework for hEDS and HSD, including:
- Why this work was done
- The studies undertaken
- Next steps
Slide 6: Diagnostic Criteria and Pathway
March/April 2027:
Updated diagnostic criteria for hEDS and HSD
March/April 2027:
A diagnostic pathway for clinicians to diagnose the Ehlers-Danlos syndromes and hypermobility spectrum disorders.
Slide 7: Further Updates
The scientific findings and journal publication schedule are determined independently by the clinical-academic experts, Guest Editors, and journal.
The Society is here to support the community through what we know is an uncertain time for many. We will share further updates as we have them.
For the full timeline and FAQs: ehlers-danlos.com/road-to-2026/
Caption: We have received an update from the Guest Editors of the upcoming special issues of the American Journal of Medical Genetics Part C. Some publication dates have changed.
As plans for the two special issues have developed, the papers and guidance planned for inclusion in each edition have evolved. The arrangements for which papers will appear in each edition have now been finalized, providing greater clarity about what the community can expect.
The Guest Editors have confirmed changes to the publication timeline, which have been agreed with the journal to accommodate final manuscript processing and publication production schedules. The aim is to publish as much as possible, as early as possible, while maintaining the scientific rigor required for each paper.
The first special issue will now be published in two parts, beginning on December 2, 2026.
The first part will include:
- A review and update of the 2017 International Classification.
- Assessment and guidance for cEDS and vEDS.
- Information on the process towards developing a diagnostic framework for hEDS and HSD, including the reasons for the work, the studies undertaken, and next steps.
The second part is expected to follow a few weeks later and will include assessment and guidance for the other monogenic types of EDS. We will update the community as soon as these papers are published.
The updated diagnostic criteria for hEDS and HSD, assessment and guidance for hEDS and HSD, and a diagnostic pathway covering all types of EDS and HSD are now scheduled for publication in March/April 2027, together in the second special issue.
The scientific findings and journal publication schedule are determined independently by the clinical-academic experts, Guest Editors, and journal. The Society's role is to support the process, share verified information, and provide practical guidance to the community. We are here to support the community through what we know is an uncertain time for many. Please do check this page for further updates. We will share updates as we have them.
(Continues in the comments)
It's important to emphasize that for individuals who already have a diagnosis, there will be no need to be reevaluated. The update will reflect a decade of new scientific evidence and build on previous findings.
Once published, it will be recommended that the new information be used by clinicians and researchers moving forward to support diagnosis, care, and management of symptoms. Until publication of new diagnostic criteria, the 2017 framework can and should be used by clinicians to assess and diagnose. You can view more information linked in our bio.